July 7, 2022
NOT-CA-22-014 - Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment
PAR-22-105 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
PAR-22-106 - Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
PAR-22-109 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to inform the extramural community of changes to the Application and Submission Information in NOT-CA-22-014 “Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment.”
An additional list of Funding Opportunity Announcements (FOAs) has been added to the existing Table in NOT-CA-22-014 under Application and Submission Information to reflect the additional 3 FOAs available for submission of applications to NOT-CA-22-014:
Application and Submission Information
Currently Reads:
This Notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through October 9, 2024.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.
|
Activity Code |
FOA Title |
First Available Due Date |
|
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) |
March 07, 2022 |
|
|
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) |
February 5, 2022 |
|
|
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) |
February 5, 2022 |
|
|
Stephen I. Katz Early Stage Investigator Research Project Grant (Clinical trial not allowed) |
January 26, 2022 |
|
|
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) |
June 07, 2022 |
|
|
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) |
February 16, 2022 |
|
|
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) |
February 16, 2022 |
|
|
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) |
February 24, 2022 |
|
|
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) |
March 16, 2022 |
|
|
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) |
May 25, 2022
|
The following Table (in bold italics) has been added to the existing Table (above) to reflect the 3 additional FOAs available for submission of applications to NOT-CA-22-014:
| Activity Code | FOA Title | First Available Due Date |
| PAR-22-105 | Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | October 5, 2022 |
| PAR-22-106 | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | October 16, 2022 |
| PAR-22-109 | Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | October 16, 2022 |
All other aspects of NOT-CA-22-014 remain unchanged.
Scientific/Research Contact(s)
Sallie J. Weaver, PhD, MHS
National Cancer Institute (NCI)
Telephone: (240) 276-6254
Email: sallie.weaver@nih.gov
Veronica Chollette, RN, MS
National Cancer Institute (NCI)
Telephone: (240) 276-6969
Email: cholletv@nih.gov
Financial/Grants Management Contact(s)
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov
and Human Services (HHS)
